Alert: Rating Upgrade (12/15/23)-Sarepta Therapeutics Inc (NASDAQ: SRPT).


Stock Rating Upgrade

The Value Trend Rating for Sarepta Therapeutics Inc (NASDAQ: SRPT) rose significantly in recent days from F to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.


Recent Price Action

Sarepta Therapeutics Inc (NASDAQ: SRPT) stock closed at $92.99 on 12/15/23 after a modest decline of -1.6%. Moreover, unusually high trading volume at 184% of normal accompanied the decline. The stock has risen 5.2% during the last week but has been weak relative to the market over the last nine months.

Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to exceed the cost of capital, SRPT is expected to be a major Value Builder.

Sarepta Therapeutics has a current Value Trend Rating of C (Low Neutral). This VT Rating improved modestly in recent days from F previously. The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Sarepta Therapeutics has a neutral Appreciation Score of 58 and a slightly negative Power Rating of 33, resulting in the Low Neutral Value Trend Rating.

Be the first to comment

Leave a Reply

Your email address will not be published.